View ValuationLabocanna 将来の成長Future 基準チェック /06現在、 Labocannaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長22.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • May 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł567k free cash flow). Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (zł2.3m revenue, or US$631k). Market cap is less than US$10m (€1.05m market cap, or US$1.22m). Minor Risk Latest financial reports are more than 6 months old (reported September 2025 fiscal period end).お知らせ • Nov 07Labocanna S.A. to Report Q3, 2025 Results on Nov 07, 2025Labocanna S.A. announced that they will report Q3, 2025 results on Nov 07, 2025Reported Earnings • Aug 12Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: zł745.9k (loss widened 251% from 2Q 2023).お知らせ • Jul 01Labocanna S.A., Annual General Meeting, Jul 24, 2024Labocanna S.A., Annual General Meeting, Jul 24, 2024.Reported Earnings • May 16First quarter 2024 earnings releasedFirst quarter 2024 results: Net loss: zł36.3k (loss widened 498% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 47% per year, which means it has not declined as severely as earnings.New Risk • Feb 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł1.3m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 8.3% per year over the past 5 years. Revenue is less than US$1m (zł17k revenue, or US$4.1k). Market cap is less than US$10m (€3.30m market cap, or US$3.55m).Reported Earnings • Feb 11Full year 2023 earnings released: zł0.028 loss per share (vs zł0.056 loss in FY 2022)Full year 2023 results: zł0.028 loss per share (improved from zł0.056 loss in FY 2022). Net loss: zł598.7k (loss narrowed 50% from FY 2022).お知らせ • Feb 02+ 4 more updatesLabocanna S.A. to Report Q3, 2024 Results on Nov 08, 2024Labocanna S.A. announced that they will report Q3, 2024 results on Nov 08, 2024New Risk • Nov 17New major risk - Revenue and earnings growthEarnings have declined by 3.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł1.6m free cash flow). Earnings have declined by 3.8% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (€1.98m market cap, or US$2.15m). Minor Risk Share price has been volatile over the past 3 months (8.7% average weekly change).New Risk • Oct 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł1.2m free cash flow). Share price has been highly volatile over the past 3 months (8.9% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€2.08m market cap, or US$2.21m).New Risk • Aug 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł1.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł1.2m free cash flow). Revenue is less than US$1m. Market cap is less than US$10m (€2.07m market cap, or US$2.27m). Minor Risk Share price has been volatile over the past 3 months (7.2% average weekly change).お知らせ • Jun 04Labocanna S.A., Annual General Meeting, Jun 27, 2023Labocanna S.A., Annual General Meeting, Jun 27, 2023, at 10:00 Central European Standard Time.お知らせ • Feb 03+ 3 more updatesLabocanna S.A. to Report Q2, 2023 Results on Aug 10, 2023Labocanna S.A. announced that they will report Q2, 2023 results on Aug 10, 2023お知らせ • May 24Labocanna S.A., Annual General Meeting, Jun 30, 2022Labocanna S.A., Annual General Meeting, Jun 30, 2022, at 09:30 Central European Standard Time.お知らせ • Sep 12Medican Campus Spolka Z Ograniczona Odpowiedzialnoscia acquired 10% stake in Labocanna S.A. (WSE:LCN) from Pawel Kicinski.Medican Campus Spolka Z Ograniczona Odpowiedzialnoscia acquired 10% stake in Labocanna S.A. (WSE:LCN) from Pawel Kicinski on September 9, 2021. Pawel Kicinski's stake has been lowered to 24.22% from 34.22%. Medican Campus Spolka Z Ograniczona Odpowiedzialnoscia completed the acquisition of 10% stake in Labocanna S.A. (WSE:LCN) from Pawel Kicinski on September 9, 2021.お知らせ • Aug 05Labocanna S.A. (WSE:LCN) acquired unknown stake in Centrum Medycyny Konopnej for PLN 0.2 million.Labocanna S.A. (WSE:LCN) acquired unknown stake in Centrum Medycyny Konopnej Spolka Akcyjna for PLN 0.2 million on August 3, 2021. Labocanna S.A. (WSE:LCN) completed the acquisition of unknown stake in Centrum Medycyny Konopnej. on August 3, 2021. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Labocanna は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:9Y2 - アナリストの将来予測と過去の財務データ ( )PLN Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/202520-10N/A6/30/202520-10N/A3/31/20251-1-10N/A12/31/202410-1-1N/A9/30/202400-2-1N/A6/30/202400-2-1N/A3/31/20240-1-2-1N/A12/31/20230-1-1-1N/A9/30/2023-1-2-2-1N/A6/30/2023-1-1-1-1N/A3/31/20231000N/A12/31/20220-100N/A9/30/20221-1-50N/A6/30/20221-1-50N/A3/31/20221-1-50N/A12/31/20210-1-6-1N/A9/30/202100-10N/A6/30/202100-10N/A3/31/202100-10N/A12/31/20200000N/A9/30/20200000N/A6/30/20200000N/A3/31/20200000N/A12/31/20190000N/A9/30/20190-100N/A6/30/20191-1N/A0N/A3/31/20191-1N/A0N/A12/31/20182-1N/A0N/A9/30/20183-1N/A0N/A6/30/20183-1N/A0N/A3/31/20184-1N/A-1N/A12/31/20174-1N/A-1N/A9/30/20175-1N/A0N/A6/30/20175-1N/A-1N/A3/31/20176-1N/A0N/A12/31/20166-1N/A0N/A9/30/201650N/A-1N/A6/30/201650N/A0N/A3/31/201650N/A1N/A12/31/201560N/A0N/A9/30/201560N/A1N/A6/30/201570N/A1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 9Y2の予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 9Y2の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 9Y2の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 9Y2の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 9Y2の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 9Y2の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/06/17 03:29終値2026/06/17 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Labocanna S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • May 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł567k free cash flow). Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (zł2.3m revenue, or US$631k). Market cap is less than US$10m (€1.05m market cap, or US$1.22m). Minor Risk Latest financial reports are more than 6 months old (reported September 2025 fiscal period end).
お知らせ • Nov 07Labocanna S.A. to Report Q3, 2025 Results on Nov 07, 2025Labocanna S.A. announced that they will report Q3, 2025 results on Nov 07, 2025
Reported Earnings • Aug 12Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: zł745.9k (loss widened 251% from 2Q 2023).
お知らせ • Jul 01Labocanna S.A., Annual General Meeting, Jul 24, 2024Labocanna S.A., Annual General Meeting, Jul 24, 2024.
Reported Earnings • May 16First quarter 2024 earnings releasedFirst quarter 2024 results: Net loss: zł36.3k (loss widened 498% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 47% per year, which means it has not declined as severely as earnings.
New Risk • Feb 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł1.3m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 8.3% per year over the past 5 years. Revenue is less than US$1m (zł17k revenue, or US$4.1k). Market cap is less than US$10m (€3.30m market cap, or US$3.55m).
Reported Earnings • Feb 11Full year 2023 earnings released: zł0.028 loss per share (vs zł0.056 loss in FY 2022)Full year 2023 results: zł0.028 loss per share (improved from zł0.056 loss in FY 2022). Net loss: zł598.7k (loss narrowed 50% from FY 2022).
お知らせ • Feb 02+ 4 more updatesLabocanna S.A. to Report Q3, 2024 Results on Nov 08, 2024Labocanna S.A. announced that they will report Q3, 2024 results on Nov 08, 2024
New Risk • Nov 17New major risk - Revenue and earnings growthEarnings have declined by 3.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł1.6m free cash flow). Earnings have declined by 3.8% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (€1.98m market cap, or US$2.15m). Minor Risk Share price has been volatile over the past 3 months (8.7% average weekly change).
New Risk • Oct 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł1.2m free cash flow). Share price has been highly volatile over the past 3 months (8.9% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€2.08m market cap, or US$2.21m).
New Risk • Aug 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł1.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł1.2m free cash flow). Revenue is less than US$1m. Market cap is less than US$10m (€2.07m market cap, or US$2.27m). Minor Risk Share price has been volatile over the past 3 months (7.2% average weekly change).
お知らせ • Jun 04Labocanna S.A., Annual General Meeting, Jun 27, 2023Labocanna S.A., Annual General Meeting, Jun 27, 2023, at 10:00 Central European Standard Time.
お知らせ • Feb 03+ 3 more updatesLabocanna S.A. to Report Q2, 2023 Results on Aug 10, 2023Labocanna S.A. announced that they will report Q2, 2023 results on Aug 10, 2023
お知らせ • May 24Labocanna S.A., Annual General Meeting, Jun 30, 2022Labocanna S.A., Annual General Meeting, Jun 30, 2022, at 09:30 Central European Standard Time.
お知らせ • Sep 12Medican Campus Spolka Z Ograniczona Odpowiedzialnoscia acquired 10% stake in Labocanna S.A. (WSE:LCN) from Pawel Kicinski.Medican Campus Spolka Z Ograniczona Odpowiedzialnoscia acquired 10% stake in Labocanna S.A. (WSE:LCN) from Pawel Kicinski on September 9, 2021. Pawel Kicinski's stake has been lowered to 24.22% from 34.22%. Medican Campus Spolka Z Ograniczona Odpowiedzialnoscia completed the acquisition of 10% stake in Labocanna S.A. (WSE:LCN) from Pawel Kicinski on September 9, 2021.
お知らせ • Aug 05Labocanna S.A. (WSE:LCN) acquired unknown stake in Centrum Medycyny Konopnej for PLN 0.2 million.Labocanna S.A. (WSE:LCN) acquired unknown stake in Centrum Medycyny Konopnej Spolka Akcyjna for PLN 0.2 million on August 3, 2021. Labocanna S.A. (WSE:LCN) completed the acquisition of unknown stake in Centrum Medycyny Konopnej. on August 3, 2021.